MacroGenics Reports Director Changes and Executive Compensation Updates
Ticker: MGNX · Form: 8-K · Filed: 2025-08-13T00:00:00.000Z
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: MGNX
TL;DR
MGNX board shakeup and pay plan changes filed today.
AI Summary
On August 13, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a departure of directors and the election of new ones, alongside adjustments to compensatory plans for certain officers. Specific details regarding the individuals involved and the financial implications of these compensatory arrangements were not fully elaborated in the provided text but are central to the report's purpose.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can sometimes precede or reflect significant strategic shifts or financial performance issues.
Key Players & Entities
- MACROGENICS, INC. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 9704 Medical Center Drive Rockville, Maryland 20850 (address) — Principal Executive Offices
- 301-251-5172 (phone_number) — Registrant's telephone number
FAQ
What specific changes were made to the board of directors?
The filing indicates a departure of directors and the election of new directors, but the specific names and number of individuals involved are not detailed in the provided text.
What are the key details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements for certain officers, but the specific details of these arrangements, including any financial impact, are not provided in the excerpt.
What is the primary reason for this 8-K filing?
This 8-K filing is primarily to report the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 13, 2025.
What is MacroGenics, Inc.'s principal executive office address?
MacroGenics, Inc.'s principal executive offices are located at 9704 Medical Center Drive, Rockville, Maryland 20850.
Filing Stats: 1,203 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2025-08-13 16:14:50
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share MGNX Nasdaq Global Select Mar
- $625,000 — r will receive an annual base salary of $625,000, which is subject to redetermination an
Filing Documents
- mgnx-20250813.htm (8-K) — 37KB
- exhibit99-1pressreleaseeri.htm (EX-99.1) — 11KB
- macrogenics20logo_jpgormata.jpg (GRAPHIC) — 136KB
- 0001125345-25-000094.txt ( ) — 354KB
- mgnx-20250813.xsd (EX-101.SCH) — 2KB
- mgnx-20250813_lab.xml (EX-101.LAB) — 21KB
- mgnx-20250813_pre.xml (EX-101.PRE) — 12KB
- mgnx-20250813_htm.xml (XML) — 3KB
01 Regulation FD Disclosures
Item 7.01 Regulation FD Disclosures. On August 13, 2025, the Company issued a press release announcing the executive changes discussed above. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated August 13, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2025 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel